This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Borella, L. Articles by Webster, R. G. Search for Related Content PubMed PubMed Citation Articles by Borella, L. Articles by Webster, R. G.

The Immunosuppressive Effects of Long-Term Combination Chemotherapy in Children with Acute Leukemia in Remission¹

Laboratories of Virology and Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee 38101

The immunosuppressive effects of maintenance combination chemotherapy given for periods ranging from 8 to 28 months to 20 children with acute lymphocytic leukemia in remission were investigated. There was depression of both the primary antibody production to the hemagglutinin antigen of the Hong Kong influenza virus and the anamnestic response to the neuraminidase of the same virus. The primary response (hemagglutination inhibition) was affected to a greater extent than the secondary (neuraminidase inhibition) response. A preferential depression of 2-mercaptoethanol-resistant hemagglutination inhibition antibodies (IgG) was also observed. One-fourth of all acute lymphocytic leukemia patients had low serum IgG levels. In vitro transformation of lymphocytes was a poor index of immunocompetence. After 2 years of continuous chemotherapy, children with low IgG and suppressed antibody production had normal response to phytohemagglutinin. This initial study on the immunocompetence of patients with leukemia undergoing long-term combination chemotherapy should provide a base line to establish correlations between immunological parameters and infectious complications.

¹ Supported by USPHS Cancer Research Center Grant CA-08480 from the National Cancer Institute, USPHS Research Grant AI-08831 from the National Institute of Allergy and Infectious Diseases, General Research Grant RR-05584 from the NIH, and by ALSAC.

Received 9/ 8/70. Accepted 12/ 3/70.

This article has been cited by other articles:

				A. L Sommer, B. K Wachel, and J. A Smith Evaluation of vaccine dosing in patients with solid tumors receiving myelosuppressive chemotherapy Journal of Oncology Pharmacy Practice, September 1, 2006; 12(3): 143 - 154. [Abstract] [PDF]

				J. J. Mazza, S. H. Yale, J. R. Arrowood, C. E. Reynolds, I. Glurich, P.-H. Chyou, J. G. Linneman, and K. D. Reed Efficacy of the Influenza Vaccine in Patients with Malignant Lymphoma Clin. Med. Res., November 1, 2005; 3(4): 214 - 220. [Abstract] [Full Text] [PDF]

				J C Chisholm, T Devine, A Charlett, C R Pinkerton, and M Zambon Response to influenza immunisation during treatment for cancer Arch. Dis. Child., June 1, 2001; 84(6): 496 - 500. [Abstract] [Full Text]

				H.P. Lin, S.D. Puthucheary, and D. Sinniah Acute Septicemic Melioidosis Occurring in a Child with Acute Lymphoblastic Leukemia Clinical Pediatrics, October 1, 1980; 19(10): 697 - 699. [Abstract] [PDF]